About
Profile
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
REGN
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Notable analyst calls this week: Southwest Airlines, Regeneron and Nvidia among top picks
- Kymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases asset
- Regeneron slumps as Wells Fargo cuts on COPD trial data
- Sanofi, Regeneron fall after late-stage data for COPD therapy
- Biohaven says anti-cancer agent cut tumor size with Regeneron’s Libtayo in Phase 1 trial
- Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea
- Trump threatens to limit imports if countries don't pay more for drugs
- Bayer wins China approval for Regeneron-partnered high-dose Eylea
- OraSure rises as seen benefitting from 23andMe/Regeneron deal
- Regeneron to buy 23andMe for $256M in court-supervised sale
- Notable analyst calls this week: Caterpillar, UnitedHealth and Peloton among top picks
- Regeneron wins over $400M jury award as Amgen found liable in antitrust case
- RFK Jr. on hot seat as he is grilled on health agency spending cuts at hearing
- Regeneron upgraded, AbbVie downgraded as Citi reviews policy risk
- Innovation, pharma profits won't suffer under Trump prescription drug EO - White House
- Regeneron Pharmaceuticals declares $0.88 dividend
- Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea
- Regeneron projects pivotal data readouts for multiple programs in 2025
- Regeneron drops as Eylea drives Q1 miss
- Regeneron Pharmaceuticals misses Q1 estimates
